The new weight-loss drug has been approved by the U.S. Food and Drug Administration to treat obesity.
By Teddy Amenabar and Lindsey Bever, The Washington PostThis image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepbound. The new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, the U.S. Food and Drug Administration announced Wednesday.
GLP-1 also increases the amount of insulin released by the pancreas after eating, slowing the rise in blood sugar.ADVERTISEMENTEarly studies by Eli Lilly suggest tirzepatide can help people lose a significant amount of body weight. In one 72-week randomized-controlled trial, people with obesity who took the highest dose of the drug lost about 21 percent of their total body weight.
In separate trials of tirzepatide and semaglutide, people taking tirzepatide lost more weight than those taking semaglutide but the data aren’t comparable because there may be differences in the study length and population, experts say. In one trial of diabetes patients that included both drugs, patients who used tirzepatide lost a little more weight than those on a low dose of semaglutide.
Mounjaro is prescribed at a low dose and then increased depending on patient tolerability. With those who experience side effects, physicians can increase the dose more slowly or not at all, experts said. Sometimes, anti-nausea medication may be prescribed. In some cases, however, patients cannot tolerate the drug and must be taken off it. In Gudzune’s experience, this is rare. “I think part of the reason I don’t see it as often is that I spend a lot of time talking about strategies to mitigate it,” she said.
Charlie Seltzer, an internist and obesity medicine specialist in Philadelphia, said he writes several prescriptions per day for Ozempic and Wegovy, but has written only three prescriptions total for Mounjaro because insurance often hasn’t covered it for weight-loss patients in the past.Most experts say people who lose weight on Mounjaro should expect to keep taking it indefinitely to keep the weight off.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, or tirzepatide.
Read more »
Eli Lilly Stock Jumps on Obesity Drug's FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
FDA Approves Weight Loss Drug Zepbound, Similar to OzempicBerkeley Lovelace Jr. is a health and medical news reporter for NBC News.
Read more »
Eli Lilly weight loss drug Zepbound approved by the FDADiabetes Drug Leads To, Significant Weight Loss in Those With Obesity, Study Finds. Researchers with Yale University recently published the results of their study in the 'New England Journal of Medicine.'. The diabetes drug tirzepatide was the focus of the study, which also included calorie restriction and 150 minutes of weekly exercise.
Read more »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
Zepbound: FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration on Wednesday approved a new version of the type 2 diabetes drug tirzepatide for use in chronic weight management, officials said.
Read more »